November 18, 2024 02:34 PM EST
People
Cell/Gene Tx

CSL Behring will close Cal­i­for­nia of­fice as part of shrink­ing ex vi­vo work

Max Bayer

Pharma Reporter

CSL Behring is clos­ing a Pasade­na, CA-based R&D site and mov­ing the op­er­a­tions to Mass­a­chu­setts as part of a larg­er repo­si­tion­ing of the com­pa­ny’s gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times